{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:47:33Z","timestamp":1790646453575,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Auton Res"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Hereditary transthyretin amyloidosis (hATTR) is a severe adult-onset progressive disease mainly involving the peripheral nervous system and the heart, with a prominent impact on the autonomic nervous system. This review summarizes the clinical aspects of autonomic dysfunction in hATTR, and their impact on quality of life as well as potential therapeutic options.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Literature review.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Autonomic dysfunction, causing neurogenic orthostatic hypotension, gastroparesis, constipation, diarrhea, bladder dysfunction, and erectile dysfunction in males, has a major impact on the quality of life of patients with hATTR. Improvement of qualify of life in patients with hATTR implies periodic symptomatic screening and early management, taking into consideration comorbidities and medication side effects. The specific effect of the disease-modifying treatment on this aspect remains to be unraveled.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Management of autonomic dysfunction in patients with hAATR is feasible and can result in improved qualify of life. Novel disease-modifying treatments for hAATR may contribute to improve autonomic dysfunction, although specific studies are required.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10286-019-00624-w","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T10:04:00Z","timestamp":1568109840000},"page":"25-31","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy"],"prefix":"10.1007","volume":"29","author":[{"given":"Thierry","family":"Gendre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Plant\u00e9-Bordeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"key":"624_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11\u201321","journal-title":"N Engl J Med"},{"key":"624_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/brain\/75.3.408","volume":"75","author":"C Andrade","year":"1952","unstructured":"Andrade C (1952) A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75:408\u2013427","journal-title":"Brain"},{"key":"624_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22\u201331","journal-title":"N Engl J Med"},{"key":"624_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/mus.22178","volume":"45","author":"AZ Burakgazi","year":"2012","unstructured":"Burakgazi AZ, Alsowaity B, Burakgazi ZA, Unal D, Kelly JJ (2012) Bladder dysfunction in peripheral neuropathies. Muscle Nerve 45:2\u20138","journal-title":"Muscle Nerve"},{"key":"624_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/lt.24058","volume":"21","author":"A Carvalho","year":"2015","unstructured":"Carvalho A, Rocha A, Lobato L (2015) Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl 21:282\u2013292","journal-title":"Liver Transpl"},{"key":"624_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/jnnp.55.9.860-a","volume":"55","author":"M Carvalho","year":"1992","unstructured":"Carvalho M, Alves M, Luis ML (1992) Octreotide\u2014a new treatment for diarrhoea in familial amyloidotic polyneuropathy. J Neurol Neurosurg Psychiatry 55:860\u2013861","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"624_CR7","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","volume":"260","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maia LF, da Silva AM, Cruz MW, Plante-Bordeneuve V, Suhr OB, Conceicao I, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Grogan DR (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260:2802\u20132814","journal-title":"J Neurol"},{"key":"624_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceicao IM, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Wilson A, Grogan DR (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79:785\u2013792","journal-title":"Neurology"},{"key":"624_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/mus.25257","volume":"55","author":"T Coelho","year":"2017","unstructured":"Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR (2017) Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle Nerve 55:323\u2013332","journal-title":"Muscle Nerve"},{"key":"624_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Conceicao","year":"2016","unstructured":"Conceicao I, Gonzalez-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L (2016) \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 21:5\u20139","journal-title":"J Peripher Nerv Syst"},{"key":"624_CR11","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1007\/s00415-007-0617-5","volume":"254","author":"C Denier","year":"2007","unstructured":"Denier C, Ducot B, Husson H, Lozeron P, Adams D, Meyer L, Said G, Plante-Bordeneuve V (2007) A brief compound test for assessment of autonomic and sensory-motor dysfunction in familial amyloid polyneuropathy. J Neurol 254:1684\u20131688","journal-title":"J Neurol"},{"key":"624_CR12","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00415-016-8375-x","volume":"264","author":"CH Gibbons","year":"2017","unstructured":"Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, Karabin B, Kuritzky L, Lew M, Low P, Mehdirad A, Raj SR, Vernino S, Kaufmann H (2017) The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol 264:1567\u20131582","journal-title":"J Neurol"},{"key":"624_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10286-018-0514-2","volume":"29","author":"A Gonzalez-Duarte","year":"2019","unstructured":"Gonzalez-Duarte A (2019) Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis). Clin Auton Res 29:245\u2013251","journal-title":"Clin Auton Res"},{"key":"624_CR14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","volume":"222","author":"D Hamon","year":"2016","unstructured":"Hamon D, Algalarrondo V, Gandjbakhch E, Extramiana F, Marijon E, Elbaz N, Selhane D, Dubois-Rande JL, Teiger E, Plante-Bordeneuve V, Damy T, Lellouche N (2016) Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. Int J Cardiol 222:562\u2013568","journal-title":"Int J Cardiol"},{"key":"624_CR15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/dme.12412","volume":"31","author":"LS Malavige","year":"2014","unstructured":"Malavige LS, Jayaratne SD, Kathriarachchi ST, Sivayogan S, Ranasinghe P, Levy JC (2014) Erectile dysfunction is a strong predictor of poor quality of life in men with type 2 diabetes mellitus. Diabetic Med 31:699\u2013706","journal-title":"Diabetic Med"},{"key":"624_CR16","first-page":"101","volume":"27","author":"S Maule","year":"2012","unstructured":"Maule S, Milazzo V, Maule MM, Di Stefano C, Milan A, Veglio F (2012) Mortality and prognosis in patients with neurogenic orthostatic hypotension. Funct Neurol 27:101\u2013106","journal-title":"Funct Neurol"},{"key":"624_CR17","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1007\/s00259-018-3963-x","volume":"45","author":"E Piekarski","year":"2018","unstructured":"Piekarski E, Chequer R, Algalarrondo V, Eliahou L, Mahida B, Vigne J, Adams D, Slama MS, Le Guludec D, Rouzet F (2018) Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers. Eur J Nucl Med Mol Imaging 45:1108\u20131118","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"624_CR18","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"V Plante-Bordeneuve","year":"2011","unstructured":"Plante-Bordeneuve V, Said G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10:1086\u20131097","journal-title":"Lancet Neurol"},{"key":"624_CR19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.nmd.2016.03.006","volume":"26","author":"M Russo","year":"2016","unstructured":"Russo M, Vita GL, Stancanelli C, Mazzeo A, Vita G, Messina S (2016) Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy. Neuromuscul Disord 26:374\u2013377","journal-title":"Neuromuscul Disord"},{"key":"624_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/08035250500440386","volume":"95","author":"SA Sands","year":"2006","unstructured":"Sands SA, Giarraffa P, Jacobson CM, Axelrod FB (2006) Familial dysautonomia\u2019s impact on quality of life in childhood, adolescence, and adulthood. Acta Paediatr 95:457\u2013462","journal-title":"Acta Paediatr"},{"key":"624_CR21","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","volume":"86","author":"Y Sekijima","year":"2015","unstructured":"Sekijima Y (2015) Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 86:1036\u20131043","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"624_CR22","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.mayocp.2012.10.013","volume":"87","author":"DM Sletten","year":"2012","unstructured":"Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W (2012) COMPASS 31: a refined and abbreviated composite autonomic symptom score. Mayo Clin Proc 87:1196\u20131201","journal-title":"Mayo Clin Proc"},{"key":"624_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2796.1994.tb01106.x","volume":"235","author":"O Suhr","year":"1994","unstructured":"Suhr O, Danielsson A, Holmgren G, Steen L (1994) Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 235:479\u2013485","journal-title":"J Intern Med"},{"key":"624_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0022-510X(99)00231-2","volume":"171","author":"K Tashima","year":"1999","unstructured":"Tashima K, Ando Y, Terazaki H, Yoshimatsu S, Suhr OB, Obayashi K, Yamashita T, Ando E, Uchino M, Ando M (1999) Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci 171:19\u201323","journal-title":"J Neurol Sci"},{"key":"624_CR25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jns5.12059","volume":"19","author":"EJ Vinik","year":"2014","unstructured":"Vinik EJ, Vinik AI, Paulson JF, Merkies IS, Packman J, Grogan DR, Coelho T (2014) Norfolk quality of life-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 19:104\u2013114","journal-title":"J Peripher Nerv Syst"},{"key":"624_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1750-1172-9-61","volume":"9","author":"J Wixner","year":"2014","unstructured":"Wixner J, Mundayat R, Karayal ON, Anan I, Karling P, Suhr OB, investigators T (2014) THAOS: gastrointestinal manifestations of transthyretin amyloidosis\u2014common complications of a rare disease. Orphanet J Rare Dis 9:61","journal-title":"Orphanet J Rare Dis"},{"key":"624_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/17474124.2018.1397511","volume":"12","author":"J Wixner","year":"2018","unstructured":"Wixner J, Suhr OB, Anan I (2018) Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single-center experience over 40 years. Expert Rev Gastroenterol Hepatol 12:73\u201381","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"624_CR28","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1111\/j.1600-6143.2007.01969.x","volume":"7","author":"S Yamamoto","year":"2007","unstructured":"Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, Gjertsen H, Soderdahl G, Wikstrom L, Ando Y, Suhr OB, Ericzon BG (2007) Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 7:2597\u20132604","journal-title":"Am J Transplant"}],"container-title":["Clinical Autonomic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-019-00624-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10286-019-00624-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-019-00624-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T09:49:47Z","timestamp":1599731387000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10286-019-00624-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":28,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["624"],"URL":"https:\/\/doi.org\/10.1007\/s10286-019-00624-w","relation":{},"ISSN":["0959-9851","1619-1560"],"issn-type":[{"value":"0959-9851","type":"print"},{"value":"1619-1560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"22 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}